The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 315.00
Bid: 315.00
Ask: 317.50
Change: -12.00 (-3.67%)
Spread: 2.50 (0.794%)
Open: 325.50
High: 329.50
Low: 315.00
Prev. Close: 327.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK inflation in November cools off record high

Wed, 14th Dec 2022 07:53

(Alliance News) - Stocks in London are set to open lower on Wednesday, ahead of a key interest rate decision by the US Federal Reserve later in the day.

The Federal Open Market Committee will conclude its two-day policy meeting on Wednesday and announce its decision at 1900 GMT. This will be followed by a press conference with Fed Chair Jerome Powell at 1930 GMT.

According to the CME FedWatch Tool, there is a 79% chance of a 50 basis point hike from the Fed, and a 21% chance a bigger hike of 75 basis points.

Should the Fed raise rates as expected by half a percent, this would take the federal funds rate range to 4.45% to 4.50%.

In Asia, China's top health body said Wednesday the true scale of coronavirus infections in the country is now "impossible" to track, with officials warning cases are rising rapidly in Beijing after the government abruptly abandoned its zero-Covid policy last week. 

Here is what you need to know ahead of the London market open:

----------

MARKETS

----------

FTSE 100: called down 14.59 points, or 0.2%, at 7,488.30

----------

Hang Seng: up 0.5% at 19,695.58

Nikkei 225: closed up 0.7% at 28,156.21

S&P/ASX 200: closed up 0.7% at 7,251.30

----------

DJIA: closed up 0.3% at 34,108.64

S&P 500: closed up 0.7% at 4,019.65

Nasdaq Composite: closed up 1.0% at 11,256.81

----------

EUR: lower at USD1.0623 (USD1.0643)

GBP: lower at USD1.2349 (USD1.2378)

USD: higher at JPY135.47 (JPY135.10)

Gold: lower at USD1,808.36 per ounce (USD1,813.25)

(Brent): lower at USD80.53 a barrel (USD81.03)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

11:00 CET EU industrial production

10:00 CET Germany IFO economic forecast

09:30 GMT UK house price index

12:15 GMT UK BoE financial stability report

07:00 EST US MBA mortgage applications survey

08:30 EST US import and export price indexes

14:00 EST US interest rate decision

----------

Inflation in the UK cooled off from last month's record annual high, according to data from the Office of National Statistics. The consumer price index rose by 0.4% in November against the previous month. Annually, CPI grew by 10.7%. Both the annual and the monthly increases undershot FXStreet-cited market consensus of 0.6% and 10.9% rises, respectively. In October, prices rose by 11.1% against the previous year, the highest annual inflation rate since the National Statistics series began in January 1997.

----------

BROKER RATING CHANGES

----------

JPMorgan cuts Taylor Wimpey to 'neutral' from 'overweight' - price target 110 (170) pence

----------

JPMorgan cuts Rio Tinto to 'underweight' from 'neutral' - price target 5,310 (5,480) pence

----------

JPMorgan cuts Redrow to 'underweight' from 'neutral' - price target 390 (550) pence

----------

COMPANIES - FTSE 100

----------

Vodafone on Tuesday said its subsidiary Oak Holdings launched a voluntary takeover offer for mobile towers business Vantage Towers. Vodafone said the price of the takeover offer is EUR32.00 per share, representing a 19% premium to the three-month volume-weighted average share price of EUR26.89. The telecommunications firm added that Oak will hold a minimum of 88.2% of the outstanding share capital of Germany-based Vantage Towers, which comprises the 81.7% stake held by Vodafone prior to the announcement of the offer.

----------

JP Sports Fashion retained its A- rating for corporate disclosure related to climate change for the third successive year from the Carbon Disclosure Project. The clothing retailer also improved its water security grade to A-. Chief Financial Officer & Chair Neil Greenhalgh said: "Our scores remain well ahead of the retail sector average, demonstrating JD's commitment and collective effort in this area." The project rates 15,000 companies for environmental disclosure.

----------

COMPANIES - FTSE 250

----------

Holiday operator Tui AG said it pretax loss for the financial year that ended September 30 narrowed to EUR146 million from EUR2.46 billion, as revenue multiplied to EUR16.55 billion from EUR4.73 billion after Covid-19 travel restrictions were lifted. Tui said it expects to operate its Winter 2022-23 programme at close to pre-pandemic levels. The Winter programme is 54% sold, which means bookings are at 134% of last year and 84% of 2018-19 levels. Tui reduced its net debt to EUR3.44 billion from EUR4.95 billion a year before.

----------

Watches of Switzerland reported double-digit rises in both interim profit and revenue, boasting "ongoing" market share gains. In the six months ended October 30, the watch retailer reported revenue of GBP765 million, up 31% from GBP586 million the previous year. Pretax profit rose 28% to GBP83 million from GBP65 million. The company also noted that trading in the holiday period so far has been in-line with its expectations. As a result, Watches of Switzerland kept its full-year guidance unchanged which expects revenue between GBP1.50 billion and GBP1.55 billion.

----------

Tullow Oil signed a production sharing contract for a new offshore exploration licence in the Ivory Coast, adjacent to its existing CI-524 licence. Tullow will operate the new CI-803 licence with a 90% interest. The remaining 10% will be held by PetroCi. Tullow said the licence strengthens its position in the Tano Basin where "significant" prospectivity has been identified. Chief Executive Rahul Dhir said: "This new licence underscores our strong commitment to investing in and unlocking the resource potential in Cote d'Ivoire. Our exploration strategy is focussed around existing producing fields in basins where we have a differentiated understanding, in this case through our deep understanding of the Tano Basin."

----------

OTHER COMPANIES

----------

Oxford BioMedica said subsidiary Oxford Biomedica Solutions has signed agreements with three unnamed US biotechnology firms. Under the agreements, the subsidiary will provide its full platform offering to support the new partners' pre-clinical gene therapy programmes. Chair & Interim Chief Executive Roch Doliveux said: "Securing four new AAV customers in 2022 exceeds our original stated target of two new customers by the end of 2022. We are making considerable progress towards becoming a global viral vector leader across all key vector types, with this momentum in Oxford Biomedica Solutions adding to the strength and depth of our UK-based operations."

----------

Holcim Ltd said it is leaving Russia by selling its business in the country to the local management team. "With its new owners, the business will operate independently under a different brand," the Zug, Switzerland-headquartered building materials manufacturer said. Holcim said its exit from Russia, which it first decided in March, is in line with its "values to operate in the most responsible manner" following Russia's invasion of Ukraine in February. The impact on overall business will be minimal as Holcim generated less than 1% of its sales and recurring earnings before interest and tax in Russia in 2021, it said.

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
1 Aug 2022 14:30

EXECUTIVE CHANGES: ReNeuron promotes CFO Catherine Isted to CEO role

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

Read more
26 Jul 2022 11:12

SMALL-CAP WINNERS & LOSERS: Reach and Wickes sink on dark outlook

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.

Read more
26 Jul 2022 11:09

Oxford BioMedica begins new project and signs license agreement

(Alliance News) - Oxford BioMedica PLC on Tuesday said it started a new project and signed a license and supply agreement.

Read more
26 Jul 2022 08:44

Oxford Biomedica inks LSA with US biotech firm, launches new project with Orchard Therapeutics

(Sharecast News) - Gene and cell therapy group Oxford Biomedica inked a new licence and supply agreement with an unnamed US private biotechnology on Tuesday company and also launched a new project with Orchard Therapeutics.

Read more
22 Jul 2022 10:36

SMALL-CAP WINNERS & LOSERS: Made.com and Hochschild slide again

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
21 Jul 2022 11:13

IN BRIEF: Oxford BioMedica shares up on deal expansion in CAR-T

Oxford BioMedica PLC - Oxford, England-based gene and cell therapy company - Expands its license and clinical supply agreement with Juno Therapeutics Inc, subsidiary of New-York based pharmaceutical industry company Bristol Myers Squibb. It says the expansion relates to the start of two new viral vector programmes for CAR-T therapies. "Oxford Biomedica will receive an undisclosed target nomination fee and potential payments upon the achievement of certain milestones," it notes.

Read more
21 Jul 2022 10:28

SMALL-CAP WINNERS & LOSERS: Go-Ahead suitor pulls out; Costain rises

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

Read more
1 Jul 2022 10:41

SMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca deal

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
1 Jul 2022 08:56

LONDON MARKET OPEN: Recession fear hits stocks; Oxford Biomedica rises

(Alliance News) - Stocks in London opened lower on Friday as investors continued to fret over prospects of a recession as central banks raise interest rates.

Read more
1 Jul 2022 08:31

Oxford BioMedica signs new Covid-19 vaccine deal with AstraZeneca

(Alliance News) - Oxford BioMedica PLC on Friday said it has signed a new three year agreement with AstraZeneca PLC, which will facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine.

Read more
1 Jul 2022 08:07

LONDON BRIEFING: Oxford Biomedica signs new Covid jab deal with Astra

(Alliance News) - Oxford Biomedica on Friday said that it has signed a new three-year agreement with AstraZeneca, which would facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine.

Read more
1 Jul 2022 07:48

LONDON MARKET PRE-OPEN: Oxford Biomedica inks new AstraZeneca jab deal

(Alliance News) - Stock prices in London are seen opening lower on Friday following another sell-off on Wall Street fuelled by recession fears, while focus will be on a slew of manufacturing PMI readings later in the day.

Read more
1 Jul 2022 07:03

Oxford Biomedica signs new Covid vaccine deal with AstraZeneca

(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.

Read more
14 Jun 2022 11:16

US FDA lifts clinical hold on Oxford BioMedica partner's trial

(Alliance News) - Oxford BioMedica PLC on Tuesday noted that the US Food & Drug Administration lifted the clinical hold on Homology Medicines Inc's pheNIX gene therapy trial.

Read more
14 Jun 2022 09:35

Oxford Biomedica sees FDA lift clinical hold on Homology's HMI-102 trial

(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Tuesday that the US Food and Drug Administration had notified Homology Medicines that the clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria had been lifted.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.